An etanercept biosimilar +/- methotrexate vs methotrexate alone in Chinese patients with moderate-to-severe rheumatoid arthritis

Trial Profile

An etanercept biosimilar +/- methotrexate vs methotrexate alone in Chinese patients with moderate-to-severe rheumatoid arthritis

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Oct 2013

At a glance

  • Drugs Etanercept (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors Hisun-Pfizer Pharmaceuticals
  • Most Recent Events

    • 26 Oct 2013 New trial record
    • 01 Jan 2013 Primary endpoint 'American-College-of-Rheumatology-20%-response-criteria' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top